Poorly differentiated thyroid carcinoma: recognition of its entity and current knowledge
Keywords:
Poorly differentiated thyroid cancer, high-risk differentiated thyroid cancer, iodine refractory, external beam radiotherapyAbstract
Poorly differentiated thyroid cancer is a unique entity within a wide-range of thyroid cancer classification with a specific pathological characteristic and criteria for diagnosis. Genetic alteration plays important roles in its development leading to either poorer response to iodine ablation or higher probability of iodine refractory, and resulting in worsened prognosis. Understanding its pathogenesis is a key to treatment planning which consists mainly of surgery, iodine ablation, and/or radiotherapy, and effective disease surveillance.
References
Arrangoiz R, Cordera F, Caba D, Muñoz M, Moreno E, de León EL. Comprehensive Review of Thyroid Embryology, Anatomy, Histology, and Physiology for Surgeons. Int J Otorhinolaryngol Head Neck Surg. 2018;7:160.
Hanks B, Salomone G. Thyroid. Sabiston textbook of surgery. New York: WB Saunders Company; 2003.
Koibuchi N. Molecular Mechanisms of Thyroid Hormone Synthesis and Secretion. Principles of Endocrinology and Hormone Action. 2016:1-9.
Schlumberger M-J, Filetti S, Alexander EK, Hay ID. Nontoxic diffuse goiter, nodular thyroid disorders, and thyroid malignancies. Williams Textbook of Endocrinology: Elsevier; 2016. p. 449-88.
Lloyd RV, Osamura RY, Klöppel G, Rosai J, Bosman FT, Jaffe ES, et al. WHO classification of tumours of endocrine organs: International Agency for Research on Cancer; 2017.
Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, et al. 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. Eur Thyroid J. 2019;8:227-45.
Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer. 2006;6:292.
Fagin JA, Wells Jr SA. Biologic and clinical perspectives on thyroid cancer. N. Engl. J. Med. 2016;375:1054-67.
Goffredo P, Roman SA, Sosa JA. Hurthle cell carcinoma: a population‐level analysis of 3311 patients. Cancer. 2013;119:504-11.
Oluic B, Paunovic I, Loncar Z, Djukic V, Diklic A, Jovanovic M, et al. Survival and prognostic factors for survival, cancer specific survival and disease free interval in 239 patients with Hurthle cell carcinoma: a single center experience. BMC Cancer. 2017;17:371.
Maximo V, Lima J, Prazeres H, Soares P, Sobrinho-Simoes M. The biology and the genetics of Hurthle cell tumors of the thyroid. Endocr Relat Cancer. 2012;19:R131-47.
Shaha AR, Ferlito A, Rinaldo A. Distant metastases from thyroid and parathyroid cancer. ORL. 2001;63:243-9.
Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 2006;13:119-28.
Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high‐risk group of papillary and follicular carcinomas. Cancer. 1983;52:1849-55
Carcangiu ML, Zampi G, Rosai J. Poorly differentiated (‘‘insular’’) thyroid carcinoma. Am J Surg Pathol. 1984;8:655–668.
Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31:1256-64.
Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 2006;106:1286-95.
Xu B, Ibrahimpasic T, Wang L, Sabra MM, Migliacci JC, Tuttle RM, et al. Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas. Thyroid 2016;26:1588-97.
Dettmer M, Schmitt A, Steinert H, Haldemann A, Meili A, Moch H, et al. Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed? Am J Surg Pathol. 2011;35:1866-72.
Bichoo RA, Mishra A, Kumari N, Krishnani N, Chand G, Agarwal G, et al. Poorly differentiated thyroid carcinoma and poorly differentiated area in differentiated thyroid carcinoma: is there any difference? Langenbecks Arch Surg. 2019;404:45-53.
Tirrò E, Martorana F, Romano C, Vitale SR, Motta G, Di Gregorio S, et al. Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice. Genes. 2019;10:709.
Soares P, Lima J, Preto A, Castro P, Vinagre J, Celestino R, et al. Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Curr Genomics. 2011;12:609-17.
Panebianco F, Nikitski AV, Nikiforova MN, Nikiforov YE. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer. Cancer Med. 2019;8:5831-9.
Valvo V, Nucera C. Coding Molecular Determinants of Thyroid Cancer Development and Progression. Clin Endocrinol Metab. 2019;48:37-59.
Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69:4885-93.
Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93:3106-16.
Ibrahimpasic T, Xu B, Landa I, Dogan S, Middha S, Seshan V, et al. Genomic alterations in fatal forms of non-anaplastic thyroid cancer: identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence. Clin Cancer Res. 2017;23:5970-80.
Khatami F, Tavangar SM. A Review of Driver Genetic Alterations in Thyroid Cancers. Iran J Pathol. 2018;13:125.
Wong KS, Lorch JH, Alexander EK, Marqusee E, Cho NL, Nehs MA, et al. Prognostic significance of extent of invasion in poorly differentiated thyroid carcinoma. Thyroid. 2019;29:1255-61.
Ito Y, Hirokawa M, Fukushima M, Inoue H, Yabuta T, Uruno T, et al. Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan. World J Surg. 2008;32:1535-43.
Walczyk A, Kopczyński J, Gąsior‐Perczak D, Pałyga I, Kowalik A, Chrapek M, et al. Poorly differentiated thyroid cancer in the context of the revised 2015 American Thyroid Association Guidelines and the Updated American Joint Committee on Cancer/Tumor‐Node‐Metastasis Staging System. Clin Endocrinol (Oxf). 2019;91:331-9.
Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer. 2004;100:950-7.
Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol. 2002;161:1549-56.
Luna-Ortiz K, Hurtado-López LM, Domínguez-Malagón H, Ramírez-Marin R, Zaldivar-Ramírez FR, Herrera-Gomez A, et al. Clinical course of insular thyroid carcinoma. Med Sci Monit. 2004;10:CR108-CR11.
Yu MG, Rivera J, Jimeno C. Poorly differentiated thyroid carcinoma: 10-year experience in a southeast asian population. Endocrinol Metab. 2017;32:288-95..
Ibrahimpasic T, Ghossein R, Carlson DL, Nixon I, Palmer FL, Shaha AR, et al. Outcomes in patients with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2014;99:1245-52..
Chen L, Wu Y-H, Lee C-H, Chen H-A, Loh E-W, Tam K-W. Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma with Clinically Uninvolved Central Neck Lymph Nodes: A Systematic Review and Meta-analysis. World J Surg. 2018;42:2846-57.
Servagi Vernat S, Khalifa J, Sun X-S, Kammerer E, Blais E, Faivre J-C, et al. 10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score Analysis. Cancers (Basel). 2019;11:849.
Justin EP, Seabold JE, Robinson RA, Walker WP, Gurli NJ, Hawes DR. Insular Carcinoma: A Distinct Thyroid Carcinoma with Associated Iodine-131. J Nucl Med. 1991;32:1358-63.
De la Fouchardière C, Decaussin-Petrucci M, Berthiller J, Descotes F, Lopez J, Lifante J-C, et al. Predictive factors of outcome in poorly differentiated thyroid carcinomas. Eur J Cancer. 2018;92:40-7.
Brierley J, Tsang R, Panzarella T, Bana N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf). 2005;63:418-27.
Lai H-W, Lee C-H, Chen J-Y, Tseng L-M, Yang A-H. Insular thyroid carcinoma: collective analysis of clinicohistologic prognostic factors and treatment effect with radioiodine or radiation therapy. J Am Coll Surg. 2006;203:715-22.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1-133.
Radowsky JS, Howard RS, Burch HB, Stojadinovic A. Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome. Thyroid. 2014;24:241-4.
Rivera M, Ricarte-Filho J, Tuttle RM, Ganly I, Shaha A, Knauf J, et al. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid. 2010;20:1085-93.
Nixon IJ, Ganly I, Patel S, Palmer FL, Whitcher MM, Tuttle RM, et al. The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. Surgery. 2011;150:1242-9.
Kowalski LP, Filho JG. Results of the treatment of locally invasive thyroid carcinoma. Head Neck. 2002;24:340-4.
Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009;74:1083-91.
Keum KC, Suh YG, Koom WS, Cho JH, Shim SJ, Lee CG, et al. The role of postoperative external-beam radiotherapy in the management of patients with papillary thyroid cancer invading the trachea. Int J Radiat Oncol Biol Phys. 2006;65:474-80.
Chow S-M, Yau S, Kwan C-K, Poon PC, Law SC. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr Relat Cancer. 2006;13:1159-72.
Terezakis SA, Lee KS, Ghossein RA, Rivera M, Tuttle RM, Wolden SL, et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2009;73:795-801.
Kiess AP, Agrawal N, Brierley JD, Duvvuri U, Ferris RL, Genden E, et al. External‐beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. Head Neck. 2016;38:493-8.
Burnett N, Dhanireddy B, Ain K, Valentino J, Gal T, Kudrimoti M. External Beam Radiation Therapy in Radioactive Iodine Refractory Thyroid Carcinoma: Long-Term Outcomes and Side Effects. Int J Radiat Oncol Biol Phys. 2017;99:E325.
Farina E, Monari F, Castellucci P, Romani F, Repaci A, Farina A, et al. 18F-FDG Pet-Guided External Beam Radiotherapy in Iodine-Refractory Differentiated Thyroid Cancer: A Pilot Study. J Thyroid Res. 2017;2017.
Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 1998;82:375-88.
Fussey JM, Crunkhorn R, Tedla M, Weickert MO, Mehanna H. External beam radiotherapy in differentiated thyroid carcinoma: a systematic review. Head Neck. 2016;38:E2297-E305.
Brierley JD, Tsang RW. External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:497-509.
Sanders Jr EM, LiVolsi VA, Brierley J, Shin J, Randolph GW. An evidence-based review of poorly differentiated thyroid cancer. World J Surg. 2007;31:934-45.
Walczyk A, Kowalska A, Sygut J. The clinical course of poorly differentiated thyroid carcinoma (insular carcinoma)-own observations. Endokrynol Pol. 2010;61:467-73.
Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D. External radiotherapy in thyroid cancers. Cancer. 1985;55:2062-71.
Simpson W, Panzarella T, Carruthers J, Gospodarowicz M, Sutcliffe S. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys. 1988;14:1063-75.
Phlips P, Hanzen C, Andry G, Van PH, Früuling J. Postoperative irradiation for thyroid cancer. Eur J Surg Oncol. 1993;19:399-404.
Farahati J, Reiners C, Stuschke M, Müller SP, Stüben G, Sauerwein W, et al. Differentiated thyroid cancer: impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer. 1996;77:172-80.
Kim T-H, Yang D-S, Jung K-Y, Kim C-Y, Choi M-S. Value of external irradiation for locally advanced papillary thyroid cancer. Int J Radiat Oncol Biol Phys. 2003;55:1006-12.
Brierley J, Tsang R, Simpson W, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 1996;6:305-10.
Ford D, Giridharan S, McConkey C, Hartley A, Brammer C, Watkinson J, et al. External beam radiotherapy in the management of differentiated thyroid cancer. Clin Oncol. 2003;15:337-41.
Meadows KM, Amdur RJ, Morris CG, Villaret DB, Mazzaferri EL, Mendenhall WM. External beam radiotherapy for differentiated thyroid cancer. Am J Otolaryngol. 2006;27:24-8.
Billan S, Charas T. External beam radiation in differentiated thyroid carcinoma. Rambam Maimonides Med J. 2016;7: e0008.
Romesser PB, Sherman EJ, Shaha AR, Lian M, Wong RJ, Sabra M, et al. External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non‐anaplastic non‐medullary thyroid cancer. J Surg Oncol. 2014;110:375-82.
Albero A, Lopéz JE, Torres A, de la Cruz L, Martin T. Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review. Endocr Relat Cancer. 2016;23:R71-R84.
Yang H, Chen Z, Wu M, Lei T, Yu H, Ge M. Remarkable response in 2 cases of Advanced Poorly Differentiated Thyroid Carcinoma with liposomal doxorubicin plus cisplatin. Cancer Biol Ther. 2016;17:693-7.
Aashiq M, Silverman DA, Na’ara S, Takahashi H, Amit M. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies. Cancers (Basel). 2019;11:1382.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621-30.
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. The Lancet. 2014;384:319-28.
Faugeras L, Pirson A-S, Donckier J, Michel L, Lemaire J, Vandervorst S, et al. Refractory thyroid carcinoma: which systemic treatment to use? Ther Adv Med Oncol. 2018;10:1758834017752853.
Lu L-C, Lee Y-H, Chang C-J, Shun C-T, Fang C-Y, Shao Y-Y, et al. Increased expression of programmed death-ligand 1 in infiltrating immune cells in hepatocellular carcinoma tissues after Sorafenib treatment. Liver cancer. 2019;8:110-20.
Kalshetty A, Basu S. Thyroglobulin “nonsecretor” metastatic poorly differentiated thyroid carcinoma with noniodine concentrating disease and aggressive clinical course: A clinical case series. Indian J Nucl Med. 2018;33:218.
Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001;11:1169-75.
Filetti S, Durante C, Hartl D, Leboulleux S, Locati L, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1856-83.
Downloads
Published
How to Cite
Issue
Section
License
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของวารสารมะเร็งวิวัฒน์ ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับ และบุคคลากรท่านอื่น ๆ ใน สมาคมฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใดๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
